Hi reader! So, how are you doing this week? I buried the hatchet with my Ataxia. I find it hard to imagine that anyone could have pity on me; I know how to take advantage of the little that I have. I am as happy as anyone, or more, after...
Dear reader! So, what’s new these days? For my part, I’m waiting for news from my editor, patiently, about the publication of the manuscript that I sent him some time ago! If you are nice, maybe I’ll talked about this new in my next blog. In the meantime, I’m going...
Useful links for tax time! We took some time to prepare reference links for the tax period. There are changes every year on tax rules and it is important for you to check if this can affect you! A tax credit is used to reduce the tax payable by the...
Neurocrine Biosciences and Voyager Therapeutic announced the formation of a strategic collaboration focused on the development and commercialization of Voyager’s gene therapy programs, VY-AADC for Parkinson’s disease and VY-FXN01 for Friedreich’s ataxia, as well as rights to two programs to be determined. This collaboration combines Neurocrine Biosciences’ expertise in neuroscience,...
Ataxia Canada: position posted on December 17, 2018. Closing date: Friday, December 28, 2018 at 4 pm Ataxia Canada – Claude St-Jean Foundation is looking for an intern – project manager Our foundation wishes to support the young talents of our organization in their quest for gainful employment. We therefore...
The article Cerebellar ataxia and intrathecal baclofen therapy: Focus on patients’ experiments, published in the online journal PLOS ONE, presents the results of a qualitative research on the impact of family ataxias on persons’ life. “The aim of this study was to elucidate and better understand patients´ experiences of living...